184 related articles for article (PubMed ID: 37491648)
21. Functional Outcome and Overall Survival in Patients with Primary or Secondary CNS Lymphoma after Surgical Resection vs. Biopsy.
Staub-Bartelt F; Rittenauer J; Sabel M; Rapp M
Cancers (Basel); 2023 Nov; 15(21):. PubMed ID: 37958439
[TBL] [Abstract][Full Text] [Related]
22. [Clinical characteristics and prognosis of 49 newly diagnosed primary central nervous system diffuse large B-cell lymphoma].
Song J; Liu H; Shen HL; Yue LZ; Yang XJ; Song WJ; Sun CY; Yu SZ; Ding K; Wang YH; Li LJ; Yu H; Shao YY; Wang CM; Yue SY; Fu R
Zhonghua Xue Ye Xue Za Zhi; 2021 Nov; 42(11):917-922. PubMed ID: 35045653
[No Abstract] [Full Text] [Related]
23. Expression of programmed cell death ligand-1 by immune cells in the microenvironment is a favorable prognostic factor for primary diffuse large B-cell lymphoma of the central nervous system.
Tsuyuki Y; Ishikawa E; Kohno K; Shimada K; Ohka F; Suzuki Y; Mabuchi S; Satou A; Takahara T; Kato S; Miyagi S; Ozawa H; Kawano T; Takagi Y; Hiraga J; Wakabayashi T; Nakamura S
Neuropathology; 2021 Apr; 41(2):99-108. PubMed ID: 33269495
[TBL] [Abstract][Full Text] [Related]
24. A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma.
Liu CJ; Lin SY; Yang CF; Yeh CM; Kuan AS; Wang HY; Tsai CK; Gau JP; Hsiao LT; Chen PM; Liu YC; Hong YC; Ko PS; Liu JH; Lin CH
Cancer Med; 2020 Mar; 9(6):2134-2145. PubMed ID: 32011103
[TBL] [Abstract][Full Text] [Related]
25. Cerebrospinal fluid soluble programmed death-ligand 1 is a useful prognostic biomarker in primary central nervous system lymphoma.
Cheng CL; Yao CY; Huang PH; Yu CW; Fang WQ; Chuang WH; Wu SJ; Lin YJ; Hung YC; Tsai CH; Yu SC; Chou WC; Tien HF
Br J Haematol; 2023 Apr; 201(1):75-85. PubMed ID: 36480431
[TBL] [Abstract][Full Text] [Related]
26. BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma.
Makino K; Nakamura H; Shinojima N; Kuroda JI; Yano S; Mikami Y; Mukasa A
J Neurooncol; 2018 Oct; 140(1):115-121. PubMed ID: 29968039
[TBL] [Abstract][Full Text] [Related]
27. [Research of prognostic immunophenotypes in 163 patients of diffuse large B-cell lymphoma].
Yang X; Chen S; Qi Y; Xu XY; Guan X; Yang YC; Liu YX; Guo YH; Gong WC; Gao YN; Wang XH; Li W; Li LF; Fu K; Zhang HL; Meng B
Zhonghua Xue Ye Xue Za Zhi; 2021 Jun; 42(6):487-494. PubMed ID: 34384155
[No Abstract] [Full Text] [Related]
28. The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings?
de Pádua Covas Lage LA; Araújo Soares V; Meneguin TD; Culler HF; Reichert CO; Jacomassi MD; Reis DGC; Zerbini MCN; de Oliveira Costa R; Rocha V; Pereira J
Radiat Oncol; 2022 Oct; 17(1):171. PubMed ID: 36273167
[TBL] [Abstract][Full Text] [Related]
29. Surgical Resection for Primary Central Nervous System Lymphoma: A Systematic Review.
Labak CM; Holdhoff M; Bettegowda C; Gallia GL; Lim M; Weingart JD; Mukherjee D
World Neurosurg; 2019 Jun; 126():e1436-e1448. PubMed ID: 30904794
[TBL] [Abstract][Full Text] [Related]
30. Primary central nervous system lymphoma in China: a single-center retrospective analysis of 167 cases.
Yuan XG; Huang YR; Yu T; Xu Y; Liang Y; Zhang XH; Sun CR; Zhao XY
Ann Hematol; 2020 Jan; 99(1):93-104. PubMed ID: 31758262
[TBL] [Abstract][Full Text] [Related]
31. Role of Rituximab in Treatment of Patients With Primary Central Nervous System Lymphoma (PCNSL): A Systematic Review and Meta-Analysis.
Zhang Y; Liu Z; Gao C; Bian H; Ma Y; Jing F; Zhao X
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):733-741. PubMed ID: 37453867
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors for primary central nervous system lymphomas treated with high-dose methotrexate-based chemo-radiotherapy.
Lee J; Shishido-Hara Y; Suzuki K; Shimizu S; Kobayashi K; Kamma H; Shiokawa Y; Nagane M
Jpn J Clin Oncol; 2017 Oct; 47(10):925-934. PubMed ID: 28981733
[TBL] [Abstract][Full Text] [Related]
33. The safety of resection for primary central nervous system lymphoma: a single institution retrospective analysis.
Cloney MB; Sonabend AM; Yun J; Yang J; Iwamoto F; Singh S; Bhagat G; Canoll P; Zanazzi G; Bruce JN; Sisti M; Sheth S; Connolly ES; McKhann G
J Neurooncol; 2017 Mar; 132(1):189-197. PubMed ID: 28116650
[TBL] [Abstract][Full Text] [Related]
34. MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.
Nosrati A; Monabati A; Sadeghipour A; Radmanesh F; Safaei A; Movahedinia S
Ann Hematol; 2019 Jan; 98(1):169-173. PubMed ID: 30306208
[TBL] [Abstract][Full Text] [Related]
35. TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.
Munch-Petersen HD; Asmar F; Dimopoulos K; Areškevičiūtė A; Brown P; Girkov MS; Pedersen A; Sjö LD; Heegaard S; Broholm H; Kristensen LS; Ralfkiaer E; Grønbæk K
Acta Neuropathol Commun; 2016 Apr; 4():40. PubMed ID: 27101868
[TBL] [Abstract][Full Text] [Related]
36. Treatment outcome and prognostic factors in PCNSL.
Niparuck P; Boonsakan P; Sutthippingkiat T; Pukiat S; Chantrathammachart P; Phusanti S; Boonyawat K; Puavilai T; Angchaisuksiri P; Ungkanont A; Chuncharunee S; Atichartakarn V
Diagn Pathol; 2019 Jun; 14(1):56. PubMed ID: 31189479
[TBL] [Abstract][Full Text] [Related]
37. Resection or Biopsy: The Efficacy of Different Surgical Approaches for Primary Central Nervous System Lymphoma.
Zhang Y; Wang Z; Wang D; Yu B; Wen J; He S; Zeng W; Wang C
Turk Neurosurg; 2024; 34(3):401-406. PubMed ID: 38650554
[TBL] [Abstract][Full Text] [Related]
38. Proposed new prognostic model using the systemic immune-inflammation index for primary central nervous system lymphoma: A prospective-retrospective multicohort analysis.
Li S; Xia Z; Cao J; Zhang J; Chen B; Chen T; Zhang X; Zhu W; Li D; Hua W; Mao Y
Front Immunol; 2022; 13():1039862. PubMed ID: 36439151
[TBL] [Abstract][Full Text] [Related]
39. MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.
Kim S; Nam SJ; Kwon D; Kim H; Lee E; Kim TM; Heo DS; Park SH; Kim CW; Jeon YK
BMC Cancer; 2016 Jun; 16():363. PubMed ID: 27286976
[TBL] [Abstract][Full Text] [Related]
40. MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma.
van der Meulen M; Dirven L; Bakunina K; van den Bent MJ; Issa S; Doorduijn JK; Bromberg JEC
J Neurooncol; 2021 Apr; 152(2):357-362. PubMed ID: 33611761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
